psilocybin therapies Archives

4 minute read

Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta’s Influence

March 29, 12:43 PM

Intranasal 5-MeO-DMT Clinical Trial Offers Hope For Treatment-Resistant Depression Partners Beckley Psytech and atai Life Sciences (NASDAQ:ATAI) have…

ATAI

3 minute read

Psilocybin Mushrooms For Sale: Is It Legal Anywhere In America?

By Lara Goldstein

February 2, 10:49 AM

Certain fungi species that spontaneously produce psilocybin, a powerful substance that activates the serotonin 5-HT2A receptor in the…

CMPS

4 minute read

Psyched: Suggestibility And Psychedelics’ Effects, EU’s $7M Research Fund, Australia’s Treatment Delivery, BZ Podcast And More

By Lara Goldstein

January 27, 11:00 AM

New study finds suggestibility plays a role in antidepressant effects of psilocybin therapy. EU invests 6.5M euros in psychedelics for pulmonary disorder, MS, ALS, and Parkinson's. Australian psychiatrists provide first psychedelic-assisted treatments in 50 years.

ATAI

2 minute read

Psychedelics Headlines: Magic Mushrooms For Sexual Wellbeing, The DEA’s Stance, The Therapist’s Role & More

By Lara Goldstein

January 8, 3:33 PM

Welcome to Benzinga's weekly psychedelics news roundup. We have pulled together several must-read news items from the last week of December 2023 and the first of January 2024.

OPTHF

2 minute read

Optimi Health Will Supply Psychedelics To Canada’s SAP, Secures CA$1M Private Financing

By Lara Goldstein

September 8, 11:15 AM

Health Canada has approved an amendment to Optimi Health’s (OTCQX: OPTHF) dealer's license, effectively allowing the company to supply MDMA and psilocybin drugs to the country’s Special Access Program (SAP.)

OPTHF

2 minute read

Second Psychedelics Merger Of The Week? Silo Wellness To Buy Jamaica-Based Business For $31.9M

By Lara Goldstein

August 29, 2:31 PM

Silo Wellness (OTCQB: SILFF) has confirmed its intention to acquire all issued and outstanding securities of NUGL Inc./Kaya Group (OTC Pink: NUGL) in an arms-length transaction valued at $31.9 (CA$43.3) million.

CYBN

2 minute read

Psilocybin For IBS Gets FDA Nod To Begin Clinical Trials At Mass. General Hospital

By Lara Goldstein

July 13, 3:48 PM

Tryp Therapeutics’ (OTCQB: TRYPF) latest Investigational New Drug (IND) application was approved by the FDA, enabling the company to begin Phase 2a clinical trials at the Massachusetts General Hospital (MGH) on the effects of psilocybin-assisted psychotherapy for adults with Irritable B

TRYPF

2 minute read

COMPASS Pathways Secures Up To $50M In Term Loan Facility With Hercules Capital

By Lara Goldstein

July 5, 1:20 PM

Mental health psychedelics biotech company COMPASS Pathways (NASDAQ: CMPS) received funding for its COMP360 Phase 3 program in Treatment-Resist

ATAI

2 minute read

UK Greenlights Phase 2 Clinical Trial On Mindset Pharma’s Psilocin Drug For Major Depression

By Lara Goldstein

June 27, 3:54 PM

Drug discovery company Mindset Pharma (OTCQB: MSSTF) received approval from the U.K.

MSSTF

3 minute read

MA, FL And OH Psychedelics Scientists And Educators’ Latest Research And Views

By Lara Goldstein

June 8, 9:44 AM

Along with a growing scientific corpus supporting the therapeutic potential of psychedelics, several states and most noticeably Massachusetts are seeing the decriminalization of natural substances via local measures.

PSYBF

Feed Tag: psilocybin therapies